Alzheimer’s Therapeutic Research Institute - News & Events

ACTC at AAIC 2024 Highlights Guide

Written by ATRI | Jul 30, 2024 5:06:05 PM

We're proud to announce that AAIC 2024 in Philadelphia will include presentations from some of our ACTC collaborators. All sessions are listed in Eastern Daylight Time and can be viewed live by both in-person and online attendees.

  • Tuesday, July 30 (8:00am – 4:15pm)
    "Comparative analysis of clinical endpoint progression rates in sporadic Alzheimer’s disease
    and Down Syndrome-related Alzheimer’s disease"
    Michael Rafii, MD, PhD,
  • Wednesday, July 31 (8:00am – 4:15pm)
    "Supporting Participants in Preclinical Alzheimer’s Trials: Experience from a Research
    Participant Advisory Board and the A4 Study"
    Sarah Walter, MSc.
  • Wednesday, July 31 (8:00am – 4:15pm)
    "Repeat Testing Reliability of Plasma pTau217 in Preclinical AD"
    Robert A. Rissman, PhD.
  • Wednesday, July 31 (8:00am – 4:15pm)
    "Relationships Between Retinal Amyloid Imaging and Amyloid PET in the A4 Trial"
    Robert A. Rissman, PhD.
  • Wednesday, July 31 (8:00am – 4:15pm)
    "Baseline Predictors of Study Discontinuation in a Preclinical Alzheimer’s Disease Clinical
    Trial"
    Rema Raman, PhD.
  • Wednesday, July 31 (9:00am – 10:30am)
    "Alzheimer's Disease and Related Dementias (ADRD) Clinical Trials Early Career
    Investigator Oral Abstracts Session"
    Rema Raman, PhD, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA and Dorene M Rentz, PsyD, Massachusetts General Hospital, Harvard Medical School, Department of Neurology, Boston, MA, USA
  • Wednesday, July 31 (4:15pm – 5:45pm)
    "Lewy body dementias: Challenges and opportunities in the era of biomarkers"
    Federico Rodriguez-Porcel, MD, Medical University of South Carolina, Charleston, SC, USA and Rema Raman, PhD, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA
  • Wednesday, July 31 (4:35pm – 4:45pm)
    "The role of imaging in outcomes and safety monitoring for preclinical intervention studies."
    Michael Rafii, MD, PhD, University of Southern California, San Diego, CA, USA; Alzheimer's Therapeutic Research Institute, San Diego, CA, USA and Prashanthi Vemuri, PhD, Mayo Clinic, Rochester, MN, USA